Rapid field testing Hememics offers a rugged, portable reader with single-use biochips and 32 sensors, enabling lab-quality results on-site within minutes. This creates sales opportunities with sectors needing quick decision-making, such as agriculture, emergency response, and military applications.

Graphene biosensor scale Partnerships like the one with General Graphene have yielded over 100,000 graphene biosensors in nine months, illustrating proven capacity to scale production. This supports upsell discussions for larger deployments or ongoing sensor supply agreements.

Seed funding traction Recent Seed 2 financing of around $2 million from TEDCO and investors signals investor confidence and potential for accelerated growth. This can open doors for co-sell opportunities, strategic partnerships, and expanded geographic reach.

Broad diagnostic focus Development includes rapid antigen and antibody diagnostics with Bluetooth-enabled connectivity, aligning with trends toward connected, portable diagnostics. Opportunities exist to target healthcare providers, field hospitals, and biotech research groups seeking integrated data workflows.

Compliance and BARDA heritage A history of collaboration with BARDA on rapid SARS-CoV-2 diagnostics suggests credibility with government and large institutional buyers. This can facilitate pursuing tenders, contracts, or pilot programs with public health and defense-related entities.